Kishan Kumar Parida

Dual targeting of cytochrome bd and bc1-aa3 terminal oxidases eradicates phenotypically diverse population of Mycobacterium tuberculosis

Bedaquiline approval paved the way for the development of drug candidates against energy metabolism pathways of TB-causing organisms, and oxidative phosphorylation was proven to be a relevant target domain. While bedaquiline acts on the F 1 F 0 ATP synthase, Q203 targets the cyto...